



ARGENICA THERAPEUTICS

ANNUAL GENERAL MEETING PRESENTATION ASX: AGN

24 NOVEMBER 2022



DISCLAIMER

This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the "Company") and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters: *this presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.*



KEY COMPANY METRICS

\$8.2M
CASH @ BANK¹

RECENT R&D REBATE
\$1.38M

PHASE 1 TRIAL
FUNDED

86.9M
SHARES ON ISSUE

\$48M
MARKET CAP²

STRONG
SHARE PRICE PERFORMANCE
SINCE IPO

(1) Cash balance as @ 30 September 2022


(2) Calculated with closing price on @ 22nd November being \$0.555



CLINICAL TRIAL ROADMAP FOR STROKE

ARGENICA HAS ACHIEVED ALL STRATEGIC PRIORITIES SET OUT AT OUR IPO

- ✓ Secured local and international **manufacturing** capabilities
- ✓ Appointed **Head of Clinical Development** to lead studies
- ✓ Built a highly experienced **clinical advisory team**
- ✓ Completed **all** required pre-clinical studies for Phase 1 clinical trial
- ✓ Received **ethics approval** to begin Phase 1 clinical trial
- ✓ **Successfully completed** first two cohorts in Phase 1 trial





PHASE 1 TRIAL UPDATE



1. FOLLOWING DOSING OF THE FIRST 2 COHORTS
NO CLINICALLY SIGNIFICANT ADVERSE EVENTS
HAVE BEEN REPORTED

2. THIRD COHORT SENTINEL GROUP
SHOWED NO SAFETY ISSUES

3. **POSITIVE DATA GENERATED TO DATE**
ALLOWING COMPANY TO PLAN FOR PHASE 2

4. FOURTH COHORT DOSING HAS BEEN
BROUGHT FORWARD



ARG-007 IS A **VERSATILE** TECHNOLOGY PLATFORM




Neuroprotective solutions targeting global unmet clinical needs.



Stroke is our lead indication and current priority.



Ability to progress multiple indications to increase value creation.






ADVANCING CLINICAL STUDIES

PHASE 1 SAFETY & DOSAGE DATA CAN POTENTIALLY BE USED TO MOVE DIRECTLY INTO MULTIPLE PHASE 2 STUDIES

STROKE

Data collected from the Phase 1 clinical trial will be critical to progress into Phase 2 trials, where ARG-007 will be **administered to stroke patients.**



1ST PRIORITY
STROKE PHASE 2



2nd PRIORITY
SIS PHASE 2

HIE


Preclinical studies have shown Argenica's ARG-007 provides neuroprotection in an animal model of Perinatal hypoxic-ischemic encephalopathy (HIE).

**86% REDUCTION
IN BRAIN CELL DEATH IN A
TERM PRECLINICAL MODEL¹**

Currently advancing pre-clinical studies required to progress a clinical program

TRAUMATIC BRAIN INJURY

Preclinical studies show that ARG-007 significantly reduced axonal injury 5 days after a single i.v. injection²



Currently advancing pre-clinical studies required to progress a clinical program

(1) Pre-clinical studies have shown ARG-007 provides neuroprotection in a term animal model of Perinatal Hypoxic Ischemic Encephalopathy (HIE) – ASX Announcement 29th September 2022.

(2) Chiu, L. S. et al (2017). *Translational neuroscience*, 8, 147-157



INVESTMENT HIGHLIGHTS



**25+ PUBLISHED
PAPERS**



**STRONG
BALANCE SHEET**




**PHASE 1
FULLY FUNDED**



**MULTIPLE
APPLICATIONS
& PIPELINE**



**POSITIVE
PHASE 1 TRIAL
PROGRESS**



**EXCEPTIONAL
& EXPERIENCED
TEAM + BOARD**



ARGENICA THERAPEUTICS

For further information please contact:

Dr Liz Dallimore

CEO & Managing Director

E: info@argenica.com.au